Loading
A phase 2 trial of RVU120 (SEL120) in myelodysplastic syndromes / neoplasms, run by GCP-Service International West GmbH, active and no longer recruiting.
RVU120 for Treatment of Anemia in Patients With Lower-risk Myelodysplastic Neoplasms is a phase 2 interventional study registered as NCT06243458 by GCP-Service International West GmbH, with 41 participants enrolled, started 2024-09-10 and due to reach its primary completion in 2026-05. Interventions recorded: RVU120 (SEL120).
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Lower-risk myelodysplastic syndromes, Myelodysplastic syndromes / neoplasms (MDS) and the tag pipeline.
Shares Lower-risk myelodysplastic syndromes, Myelodysplastic syndromes / neoplasms (MDS) and the tag pipeline.
Shares Ryvu Therapeutics and the tag pipeline.
Shares Ryvu Therapeutics and the tag pipeline.
Shares Myelodysplastic syndromes / neoplasms (MDS) and the tag pipeline.
Shares Myelodysplastic syndromes / neoplasms (MDS) and the tag pipeline.
Shares Myelodysplastic syndromes / neoplasms (MDS) and the tag pipeline.
Shares Myelodysplastic syndromes / neoplasms (MDS) and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/